This open-label study (n=16) assessed the effects of a single dose of psilocybin (15mg/70kg) on biomarkers of inflammation in healthy participants. Blood samples before and one day after the administration revealed that psilocybin did not significantly impact any of the selected biomarkers.
- Published
- Journal
- Comprehensive Psychoneuroendocrinology
- Authors
- Aripaka, S. S., Burmester, D., Elfving, B., Fisher, P. M., Frokjaer, V. G., Knudsen, G. M., Madsen, M. K., Mikkelsen, J. D., Stenbæk, D. S., Szabo, A.